Abbisko Therapeutics
2256 · HKEX
Public Market Listing
2256HKEX
Live quotes, historical charts, and market capitalization for Abbisko Therapeutics are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | FGFR2 / FGFR3Small molecule | Non-Small Cell Lung CancerAchondroplasia | |
| Phase 2 | PD-1/PD-L1 interactionSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFR exon 20 insertionSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Est. primary completion 2027-12-30 · NCT06668103 · CT.gov ↗
What to watch
2028 (2)
2029 (2)
November 2029 (1)
Lumipodlin + LavengratinibPhase 2HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Est. primary completion 2029-11-30 · NCT06632262 · CT.gov ↗
What to watch
December 2029 (1)
Est. primary completion 2029-12-31 · NCT07710612 · CT.gov ↗